90 related articles for article (PubMed ID: 27539038)
1. [Comparative Study of the Antiemetic Palonosetron for Lung Cancer Patients Treated with a Divided Dose of Cisplatin].
Umehara K; Wakamoto A; Hatsuyama T; Sato H; Kobayashi M; Fujita A; Sekine K
Gan To Kagaku Ryoho; 2016 Aug; 43(8):967-72. PubMed ID: 27539038
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
3. Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Blazer M; Phillips G; Reardon J; Efries D; Smith Y; Weatherby L; Juergens K; Rose J; Griffith N; Bekaii-Saab T
Oncology; 2012; 83(3):135-40. PubMed ID: 22814309
[TBL] [Abstract][Full Text] [Related]
4. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
5. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
Einhorn LH; Brames MJ; Dreicer R; Nichols CR; Cullen MT; Bubalo J
Support Care Cancer; 2007 Nov; 15(11):1293-1300. PubMed ID: 17436025
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study.
Kitayama H; Tsuji Y; Sugiyama J; Doi A; Kondo T; Hirayama M
Int J Clin Oncol; 2015 Dec; 20(6):1051-6. PubMed ID: 25822106
[TBL] [Abstract][Full Text] [Related]
7. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
8. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
9. Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
Kubota K; Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T
Support Care Cancer; 2016 Sep; 24(9):4025-33. PubMed ID: 27129842
[TBL] [Abstract][Full Text] [Related]
10. Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.
Hatoum HT; Lin SJ; Buchner D; Cox D
Support Care Cancer; 2012 May; 20(5):941-9. PubMed ID: 21533811
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of an antiemetic NK1 receptor-antagonist in lung cancer patients treated with divided doses for Cisplatin].
Sato H; Wada K; Umehara K; Otsu K; Wakamoto A; Hatsuyama T; Fujita A; Sekine K
Gan To Kagaku Ryoho; 2013 Jun; 40(6):733-6. PubMed ID: 23863648
[TBL] [Abstract][Full Text] [Related]
12. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
13. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin.
Hashizume J; Higuchi N; Sato K; Kodama Y; Matsunaga N; Sakamoto T; Yamaguchi K; Nakamura T; Kitahara T; Sasaki H
Biol Pharm Bull; 2016; 39(4):611-4. PubMed ID: 27040634
[TBL] [Abstract][Full Text] [Related]
16. [The efficacy of aprepitant and palonosetron on cisplatin doublet in lung cancer].
Suzuki C; Hiura K; Sato H; Komori H; Yamamoto M
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1653-7. PubMed ID: 21996961
[TBL] [Abstract][Full Text] [Related]
17. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
18. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
Craver C; Gayle J; Balu S; Buchner D
J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer.
Murakami M; Hashimoto H; Yamaguchi K; Yamaguchi I; Senba S; Siraishi T
Support Care Cancer; 2014 Apr; 22(4):905-9. PubMed ID: 24240649
[TBL] [Abstract][Full Text] [Related]
20. Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Komatsu Y; Okita K; Yuki S; Furuhata T; Fukushima H; Masuko H; Kawamoto Y; Isobe H; Miyagishima T; Sasaki K; Nakamura M; Ohsaki Y; Nakajima J; Tateyama M; Eto K; Minami S; Yokoyama R; Iwanaga I; Shibuya H; Kudo M; Oba K; Takahashi Y
Cancer Sci; 2015 Jul; 106(7):891-5. PubMed ID: 25872578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
